Welcome to our dedicated page for ARVINAS SEC filings (Ticker: ARVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on ARVINAS's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into ARVINAS's regulatory disclosures and financial reporting.
Arvinas, Inc. Chief Accounting Officer David K. Loomis reported an automatic sale of common stock tied to tax withholding. On February 23, he sold 1,108 shares of Arvinas common stock at $12.16 per share. The sale was made by the company to cover tax obligations arising from the vesting and settlement of one-half of his restricted stock units granted on February 23, 2024, and did not represent a discretionary trade. After this transaction, Loomis directly holds 29,692 Arvinas common shares.
ARVINAS, INC. Chief Scientific Officer Angela M. Cacace reported automatic sales of a total of 3,609 shares of common stock at $12.16 per share. These transactions were made by the company to cover tax withholding on vesting restricted stock units and did not represent discretionary trades.
Arvinas, Inc. President and CEO Randy Teel reported two open-market sales of common stock linked to equity award vesting. On February 23, 2026, he sold 1,038 shares and 3,748 shares at $12.16 per share, totaling 4,786 shares.
According to the footnotes, both sales were made automatically by the company to cover tax withholding obligations upon vesting and settlement of restricted stock units granted on February 22, 2023 and February 23, 2024, and do not represent discretionary trades.
Arvinas, Inc. reports a year focused on advancing its PROTAC protein degradation pipeline while remaining deeply loss‑making. The company is still pre‑revenue from product sales and recorded net losses of $80.8 million in 2025, $198.9 million in 2024 and $367.3 million in 2023, and expects operating losses for at least several more years.
Its most advanced candidate, vepdegestrant, has a New Drug Application accepted by the FDA for ESR1‑mutated ER+/HER2‑ advanced or metastatic breast cancer, with a PDUFA action date of June 5, 2026. Arvinas highlights a broad clinical pipeline, including ARV‑102 for Parkinson’s disease and PSP, ARV‑806 for KRAS G12D‑mutated solid tumors, ARV‑393 for non‑Hodgkin lymphoma and ARV‑027 for spinal bulbar muscular atrophy, plus multiple preclinical neurology, oncology, and immuno‑oncology programs. Management believes existing cash, cash equivalents and marketable securities can fund planned operations into the second half of 2028, but substantial additional capital will ultimately be required.
Arvinas, Inc. reported 2025 results showing a sharply reduced net loss and a stronger balance sheet to support its PROTAC pipeline. Full-year revenue was $262.6 million, roughly flat with 2024, while the net loss narrowed to $80.8 million from $198.9 million as both R&D and G&A expenses declined.
Year-end cash, cash equivalents and marketable securities totaled $685.4 million, and the company expects this to fund operations into the second half of 2028. Arvinas highlighted multiple clinical programs, including ARV-102, ARV-806, ARV-393, ARV-027 and ARV-6723, as well as vepdegestrant, which has an FDA PDUFA action date of June 5, 2026.
The company also appointed Randy Teel, Ph.D., as President and CEO, continued progressing four ongoing clinical trials, initiated a Phase 1 study for ARV-027, and prepared to move its first immuno-oncology candidate ARV-6723 into the clinic, underscoring an active late- and mid-stage pipeline.
Arvinas, Inc. submitted a Form 144 notifying the proposed sale of 3,609 shares of common stock in connection with the settlement of vested restricted stock units on 02/23/2026. The filing also reports a prior sale of 4,592 shares on 02/13/2026. The broker listed is Morgan Stanley Smith Barney LLC.
Arvinas, Inc. filed a notice for the proposed sale of 4,786 common shares through Morgan Stanley Smith Barney LLC, reflecting the settlement of vested restricted stock units on 02/23/2026.
The filing also reports an earlier sale by Randy Teel of 4,403 common shares on 02/13/2026 for $52,359.96.
ARVINAS, INC. President and CEO Randy Teel reported an automatic sale of 4,403 shares of common stock on February 13, 2026 at $11.89 per share. According to the filing, the issuer executed this sale solely to cover tax withholding obligations tied to the vesting and settlement of 25% of his restricted stock units granted on February 13, 2026, and it was not a discretionary trade. Following this transaction, Teel beneficially owned 154,482 shares of Arvinas common stock directly.
Arvinas, Inc.’s Chief Financial Officer Andrew Saik reported an automatic share sale related to tax withholding. On February 13, 2026, 5,134 shares of common stock were sold at $11.89 per share to cover tax obligations triggered by the vesting and settlement of 25% of his restricted stock units granted on February 13, 2025. The filing notes this was not a discretionary trade. After this transaction, Saik’s directly held stake is 159,267 shares of Arvinas common stock.
Arvinas, Inc. Chief Scientific Officer Angela M. Cacace reported an automatic sale of common stock tied to tax withholding. On February 13, 2026, 4,592 shares of common stock were sold in an open-market transaction at $11.89 per share to cover tax obligations from RSU vesting. After this transaction, Cacace directly owned 151,232 common shares, which include 1,576 shares previously acquired under the company’s 2018 Employee Stock Purchase Plan. The filing notes the sale did not represent a discretionary trade.